|
|
|
|
Дата |
|---|
| 22:08 |
| 25.08.2026 |
| 24.08.2026 |
| 21.08.2026 |
| 20.08.2026 |
| 19.08.2026 |
| 18.08.2026 |
| 17.08.2026 |
| 14.08.2026 |
| 13.08.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
12.46
|
12.58
|
12.47
|
11.71
|
12.54
|
12.53
|
|
|
6 968 417.58
|
6 043.00
|
|
12.00
|
12.75
|
11.47
|
11.35
|
12.74
|
12.54
|
|
|
8 645 880.44
|
7 957.00
|
|
10.65
|
11.55
|
11.21
|
10.51
|
11.44
|
11.36
|
|
|
6 313 245.78
|
8 139.00
|
|
10.90
|
11.50
|
11.35
|
11.065
|
11.61
|
11.21
|
|
|
4 899 904.76
|
6 061.00
|
|
10.90
|
11.45
|
12.07
|
10.96
|
12.2093
|
11.23
|
|
|
6 243 700.76
|
6 684.00
|
|
11.40
|
12.40
|
12.11
|
11.69
|
12.32
|
12.15
|
|
|
10 779 045.97
|
8 655.00
|
|
11.36
|
12.06
|
11.20
|
11.08
|
11.93
|
11.82
|
|
|
6 398 254.20
|
7 444.00
|
|
11.00
|
11.70
|
11.76
|
10.96
|
11.7868
|
11.245
|
|
|
6 947 961.77
|
8 309.00
|
|
11.00
|
12.20
|
12.04
|
11.23
|
12.25
|
11.75
|
|
|
5 243 140.59
|
7 208.00
|
|
11.50
|
12.00
|
11.92
|
11.51
|
12.32
|
11.58
|
|
|
5 884 507.97
|
7 105.00
|
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded by leading experts in psychiatry and neuroscience, dedicated to addressing significant unmet medical needs in central nervous system (CNS) disorders. The firm’s proprietary discovery platform-leveraging optogenetics, spatial transcriptomics (STARmap) and circuit-based neuroscience-aims to identify and modulate the specific neural circuits underlying diseases. Their lead candidate, ML-007C-MA (an M/M muscarinic agonist co-formulated with a peripherally acting anticholinergic), is currently in Phase 2 development for indications including schizophrenia and Alzheimer’s disease psychosis.
The company is headquartered in Redwood City, California, and recently completed a large Series D financing of US $372.5 million to advance its pipeline.
Показать все Скрыть